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Abstract
Purpose
Thyroglobulin measurement in fine-needle aspiration washout fluid (FNA-Tg) is widely used
for detection of lymph node metastasis (LNM) in patients with papillary thyroid cancer
(PTC). Recent studies suggested that serum anti-thyroglobulin antibodies (TgAbs) could
interfere with FNA-Tg. We evaluated whether TgAbs can affect FNA-Tg when diagnosing
LNM in postoperative patients with PTC.
Methods
From November 2006 to June 2011, a total of 239 LNs from 201 patients who underwent
bilateral thyroidectomy and radioactive iodine ablation therapy were included. The interac-
tions between FNA-Tgs and serum TgAbs, and diagnostic performances between FNA with
additional FNA-Tg and FNA alone according to the presence of serum TgAbs were evalu-
ated using the generalized linear mixed model and the bootstrap method.
Results
From 106 (44.4%) malignant and 133 (55.6%) benign LNs, there were 32 (13.4%) LNs with
detectable serum TgAb levels and 207 (86.6%) LNs with undetectable serum TgAb levels.
In logistic regression analysis, a significant negative interaction was observed between
FNA-Tgs and serum TgAbs (p = 0.031). In the absence of serum TgAbs, the diagnostic per-
formances were superior in the FNA with FNA-Tg than in the FNA only. However, in the
presence of serum TgAbs, the diagnostic performances of the FNA with FNA-Tg were not
significantly different from the FNA only, even with a different cutoff value of FNA-Tg.
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Conclusions
Serum TgAbs may interfere with FNA-Tg studies and caution is advised while analyzing
FNA-Tg for detection of LNM in patients with PTC.
Introduction
Papillary thyroid carcinoma (PTC) usually has a good prognosis with indolent course. How-
ever, loco-regional recurrence is not negligible, ranging from 5–20% in patients who undergo
surgery for PTC [1, 2]. The most frequently involved site of loco-regional metastasis of PTC is
the neck, and the incidence of lymph node metastasis (LNM) is relatively high with values
reported from 3.1% to 28.9%, which can influence the prognosis [3–5]. Therefore, several
methods are generally used to detect metastases or recurrences of PTC, such as diagnostic
whole body scan, neck ultrasonography (US) and serum thyroglobulin (Tg) measurements [6–
10].
To diagnose loco-regional lymph node metastases, ultrasound-guided fine-needle aspiration
(US-FNA) is essential, but 5–10% of nondiagnostic results and 6–8% of false-negative results
have also been found with the procedure [11, 12]. Therefore, an additional test of Tg measure-
ments in FNA washout fluid (FNA-Tg) is widely used with a high sensitivity (88.3–96.1%) and
specificity (81.6–96%) for detection of early LNM in patients with PTC after thyroid surgery as
well as before thyroid surgery [12–19]. Serum anti-Tg antibodies (TgAbs) are present in
approximately 10% of the general population and 25% of thyroid cancer patients [10, 20].
Although it is already well known that serum TgAbs can falsely lower serum Tg measurements,
serum TgAbs have not been thought to influence the detection of FNA-Tgs [7, 10]. Recently,
however, it has been suggested in some studies that high serum TgAbs above 20 and 60 IU/mL
can interfere with FNA-Tg measurements [21, 22]. Therefore, the aim of our study was to eval-
uate whether serum TgAbs can affect FNA-Tg detection for diagnosing LNM in postoperative
patients with papillary thyroid cancer.
Materials and Methods
The institutional review board of Severance hospital approved of this retrospective observa-
tional study and required neither patient approval nor informed consent for our review of
patients’ images and patients’ medical records. However, written informed consent was
obtained from all patients for US-FNAs prior to each procedure as part of our hospital’s daily
practice. Our institutional review board waived the need for written informed consent from
the patients. Patients' records and information were anonymized and de-identified prior to
analysis.
Patients
From November 2006 to June 2011, 210 consecutive patients underwent FNA and FNA-Tg
measurements to detect lymph node recurrences of PTC at our institution (a referral center).
All patients underwent bilateral thyroidectomy and remnant ablation with radioactive iodine
[131-iodine (131I)]. Eight patients were excluded because they did not undergo surgical excision
or long-term imaging follow-up for at least 1 year. One patient was also excluded because she
had another malignancy. Of the 239 LNs in 201 patients, 170 patients had one LN, 24 had two
LNs and 7 had 3 LNs. Of the 201 patients, 8 patients had both malignant and benign LNs (6
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patients had one malignant and one benign LN, one patient had two malignant and one benign
LNs, and one patient had one malignant and two benign LNs). One hundred twelve patients
had benign LNs only (102 patients had one benign LN, 8 patients had two, and 2 patients had
three benign LNs), and 81 patients had malignant LNs only (68 patients had one malignant
LN, 10 patients had two, and 3 patients had three malignant LNs). Patients ranged in age from
20 to 83 years (mean, 48.3 years).
Ultrasound-guided fine needle aspiration with Tg test
US-FNAs were performed by one of 21 radiologists who were aware of the patients’ clinical his-
tory. US-FNAs were performed with a 23-gauge needle attached to a 2-mL disposable plastic
syringe. Each cervical lymph node was aspirated at least twice. The materials obtained from
FNA were smeared on glass slides for conventional cytology. All smears were placed in 95%
alcohol for Papanicolaou staining and the remaining aspirates in the syringe and needle were
rinsed with normal saline and 1 mL of rinsed washout was submitted for Tg measurement
(FNA-Tg) [12, 16]. All patients were taking levothyroxine for TSH suppression at the time of
FNA-Tg measurement.
Biochemical analysis
Serum Tg and FNA-Tg were assayed with a monoclonal antibody immunoradiometricassay
(IRMA; CIS Bio International, Gif-sur-Yvette, France). Analytical sensitivity, defined as the
smallest detectable concentration different from zero with a probability of 95%, was 0.2 ng/ml.
Functional sensitivity, calculated with the imprecision profile for a coefficient of variation
equal to 20%, was 0.7 ng/ml [12, 14, 16, 17, 23]. Serum TgAbs were measured by radioimmu-
noassay (Brahms, Hennigsdorf/Berlin, Germany) with a functional sensitivity of 10 IU/mL:
antibody positivity was defined as a TgAb value exceeding 60 U/mL [24]. Serum TSH levels
were measured by a radioimmunoassay (Trinity Biotech, Co. Wicklow, Ireland) with a refer-
ence range of 0.4–3.1 μIU/mL and a functional sensitivity of 0.0038 mIU/L.
Cytology and pathology
Positive cytology was defined as a metastasis from thyroid carcinoma or foamy macrophages
without malignant cells in the cytology report [23, 25–27]. A previous study showed that
metastasis on a pathologic report could be proven not only with a previous cytology result of
metastasis, but also with foamy macrophages without malignant cells [23]. Negative cytology
included benign cytology such as reactive hyperplasia, and other benign lymphadenitis. In
addition, we included the non-diagnostic cytology of paucicellular cytology from insufficient
material to the negative cytology category because cytology results revealed no definite malig-
nant cells.
Positive diagnoses were made based on histological or cytological findings. Negative diagno-
ses were based on no evidence of malignant LN on histological findings or absence of evolution
or decrease on US without cytological evidence of malignancy at 1 year or more of follow-up
[23, 28].
Data and Statistical Analysis
Patients with detectable serum TgAbs (sTgAb+) and undetectable serum TgAbs (sTgAb-) were
compared according to patient characteristics. Categorical variables were summarized by fre-
quencies and percentages. Continuous variables were presented as means ± standard deviation
(SD) or as medians with interquartile range. We used the χ2 test to determine differences
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between metastatic and benign lymph nodes according to categorical variables. For those val-
ues not normally distributed, a nonparametric method such as the Mann-Whitney U test was
used. The independent two-sample t-test was used to compare patient characteristics between
the two groups.
Values with a skewed distribution were logarithmically transformed and analyzed. Normal-
ity of the variables was tested using the Kolmogorov-Smirnov test. Values of FNA-Tgs were
logarithmically transformed before analyses to adjust for skewed distributions. To examine
whether the associations between FNA-Tgs and metastases were modified by serum TgAbs, we
tested their interactions on a multiplicative scale. Specifically, the interaction term for FNA-Tg
x TgAb was included in the generalized linear mixed model for binary data, considering the
correlation between the LNs of the same patients.
Due to the interaction between FNA-Tgs and serum TgAbs, we divided cases into the
sTgAb+ group and sTgAb- group. Receiver operating characteristic (ROC) analyses were per-
formed to determine the cutoff values of FNA-Tg to diagnose malignant LNs in the two groups,
respectively. Youden’s method was used to find an optimal cutoff point in the ROC curve to
maximize sensitivity and specificity. The area under the ROC curves (AUCs) of the groups
were also obtained with confidence intervals. The diagnostic performances of FNA-Tg at an
optimal cutoff point in the ROC curves were assessed by calculating sensitivity, specificity,
accuracy, positive predictive value (PPV) and negative predictive value (NPV) for each group
separately. We compared the diagnostic performances of FNA-Tg according to the presence of
serum TgAbs and also compared diagnostic performances between the FNA only group and
the FNA with additional FNA-Tg group using the generalized linear mixed model for binary
data. To compare AUCs, the bootstrap method was used with resampling done 1000 times. P
values were computed on the basis of 1000 bootstrap samples.
For all analyses, results were considered statistically significant if the p value was< 0.05. For
statistical analysis, we used a computerized statistics program (SAS version 9.2 for Windows;
SAS Institute, Cary, NC).
Results
In this study, 239 LNs in 201 patients were included. There were 106 (44.4%) malignant LNs
and 133 (55.6%) benign LNs. From those 106 LNs which were classified as malignant in our
study, 3 LNs had cytology results of ‘paucicellular smear showing several scattered hemosid-
erin-laden macrophages’. However, the final pathology after excision of suspected LNs turned
out to be metastatic carcinomas from papillary thyroid carcinoma in these three LNs. S1 Mate-
rial showed the part of detailed information of the patients including their FNA-Tg and TgAb
levels. Table 1 showed the clinical characteristics and US features of the LNs without and with
metastasis. On univariate analysis, LNMs were significantly associated with male gender, larger
primary tumor size, presence of lymph node metastasis at the initial operation, and higher
serum Tg levels (Table 1).
There were 32 (13.4%) LNs in the sTgAb+ group and 207 (86.6%) LNs in the sTgAb- group.
The value of the FNA-Tg level in metastatic LNs was 347.9 ± 189.9 ng/mL (243.9 ± 224.2 ng/
mL in the sTgAb+ group, 366.3 ± 178.2 ng/mL in the sTgAb- group). The value of the FNA-Tg
level in benign LNs was 1.2 ± 5.1 ng/mL (5.7 ± 13.9 ng/mL in the sTgAb+ group, 0.5 ± 1.2 ng/
mL in the sTgAb- group). For diagnosing LNM, there were significant interactions between
FNA-Tgs and serum TgAbs (p = 0.022 without adjusting lymph node size, p = 0.031 with
adjusting size) in logistic regression analyses. The odd ratios (OR) for the prediction of LNMs
using FNA-Tgs were decreased from 2.685–2.780 in the sTgAb- group to 1.707–1.779 in the
sTgAb+ group. In the subgroup analysis, the ORs of FNA-Tg were 2.685 for the prediction of
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LNMs in the sTgAb- group (95% CI 2.102–3.428, p< 0.001) and 1.707 in the sTgAb+ group
(95% CI 1.105–2.637, p = 0.027) on univariate analysis. On multivariate analysis, the ORs of
FNA-Tg were 2.780 in the sTgAb- group (95% CI 2.130–3.629, p< 0.001), and 1.779 in the
sTgAb+ group (95% CI 1.013–3.124, p = 0.047).
The distribution of FNA-Tg levels was shown according to the presence of serum TgAbs
(Fig 1). The cutoff values of FNA-Tg for the prediction of LNMs were 19.9 [= exp (2.989)] ng/
mL in the all and sTgAb- group and 38.3 [= exp (4.256)] ng/mL in the sTgAb+ group. Of the 32
LNs in the sTgAb+ group, 4 out of 16 metastatic LNs (25%) had FNA-Tg levels less than 38.3
ng/mL. Furthermore, of the 207 LNs in the sTgAb- group, 8 out of 90 metastatic LNs (8.9%)
had FNA-Tg levels less than 19.9 ng/mL. In addition, of the 32 LNs in the sTgAb+ group, 1 out
of 16 benign LNs (6.3%) had a FNA-Tg level higher than 38.3 ng/mL, and of the 207 LNs in
the sTgAb- group, no LNs from the 117 benign LNs (0%) showed a FNA-Tg level higher than
19.9 ng/mL in our study. When applying the cutoff value of 19.9 ng/mL, all diagnostic perfor-
mances except sensitivity were significantly increased for diagnosing LNMs in the sTgAb-
group compared with those in the sTgAb+ group (Table 2). Sensitivity was also increased
although without statistical significance. The predictive power of FNA-Tgs in the sTgAb-
group (AUC 0.956; 95% CI 0.924–0.983) was significantly superior to that of the sTgAb+ group
(AUC 0.814; 95% CI 0.670–0.941) in predicting LNMs (p = 0.024). When a cutoff value of 38.3
ng/mL of FNA-Tgs in sTgAb+ was applied, specificity, PPV, NPV and diagnostic accuracy
were significantly decreased in the sTgAb+ group with a cutoff value of 38.3 ng/mL, compared
to the sTgAb- group with a cutoff value of 19.9 ng/mL.
Additionally, we compared diagnostic performances between FNA alone and FNA with
additional FNA-Tgs (Table 3). When we included all groups, the combination of FNA and
FNA-Tgs with a cutoff value of 19.9 ng/mL showed significantly superior sensitivity and NPV
to FNA cytology alone (p = 0.012 and 0.013, respectively). In the sTgAb- group, the combina-
tion of FNA and FNA-Tgs with a cutoff value of 19.9 ng/mL showed significantly superior sen-
sitivity, NPV, accuracy (all, p = 0.02) and AUC (p< 0.001), to FNA alone. In the sTgAb+
Table 1. Patient Characteristics according to Final Diagnosis.
Characteristics Malignancy Benign P value
Number of patients, n 86 115
Number of LNs, n 106 133
Gender, male/female (%) 38/68 (35.8) 28/105 (21.1) 0.011b
Mean age, years 47.4±14.4 (20–83) 49.1±12.9 (20–78) 0.340 c
Primary tumor a
Size, mm (range) 18.6 ± 12.2 (3–24) 14.3 ±11.0 (3–31) 0.020 c
Multiplicity, yes/no (%) 23/42 (35.4) 34/62 (35.4) 0.997b
LN metastasis, yes/no (%) 54/11 (83.1) 62/34 (64.6) 0.010b
Extrathyroid extension, yes/no (%) 45/20 (69.2) 64/32 (66.7) 0.733b
Serum Tg, ng/ml (interquartile range) 0.7 (3.3) 0.2 (0.1) < 0.001d
Serum Tg antibody, yes/no (%) 16/90 (15.1) 16/117 (12.0) 0.489b
Results are expressed as number (percent), mean ± standard deviation (range) or median (interquartile range)
aEvaluation of the characteristics of the primary tumor was possible for 123 LNs in 121 patients who had available initial operation data.
bDerived from the Chi-square test.
cDerived from the Student’s t test.
dDerived from the Mann-Whitney U test.
LN, lymph node; Tg, thyroglobulin.
doi:10.1371/journal.pone.0131096.t001
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Fig 1. The distribution of FNA-Tg in lymph nodemetastasis and benign groups according to the
TgAb. (A) Comparison of FNA-Tg levels in all groups. (B) Comparison of FNA-Tg levels in the sTgAb- group.
(C) Comparison of FNA-Tg levels in the sTgAb+ group. The cutoff values of FNA-Tg between malignant and
benign lymph nodes were presented as arrows (19.9 [= exp (2.989)] ng/mL in a, 19.9 [= exp (2.989)] ng/mL in
Antithyroglobulin Antibodies in Lymph Node Metastasis
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group, diagnostic performances of the combination of FNA and FNA-Tgs with a cutoff value
of 38.3 ng/mL were not significantly different from those of FNA cytology alone.
Discussion
Additional FNA-Tg measurements to FNA are well known to have high sensivity, NPV and
accuracy when predicting LNMs in the patients who undergo thyroidectomy or not, when
compared to performing FNA alone (Table 4) [7, 8, 12, 14, 15, 18, 22]. However, there have
only been a few studies about whether serum TgAbs can influence FNA-Tg detection [7, 10,
21, 22]. Baskin first investigated the role of FNA-Tgs in detecting recurrent PTCs at suspicious
lymph nodes in 21 patients who had undergone a total or near-total thyroidectomy followed
by 131I ablation [10]. In that study, serum TgAbs did not interfere with FNA-Tg measurements
when diagnosing recurrences in the neck and he speculated that intracellular Tg might not be
exposed to circulating TgAbs [10]. Then, Boi et al. evaluated the usefulness of FNA-Tg in rela-
tion to the presence of serum TgAbs for LNM diagnosis in 73 patients with differentiated thy-
roid carcinoma before and after thyroidectomy [7]. Serum TgAbs were detected in FNA
washout fluids in at least 25% of patients and Boi et al. suggested the possibility of contamina-
tion of blood or FNA washout fluid analysis by serum TgAbs [7]. However, they concluded
that serum TgAbs did not lower the sensitivity and specificity of FNA-Tg measurements,
because the FNA-Tg levels in patients with serum TgAbs were high enough to diagnose LNMs
[7].
Contrary to the conclusions reached in these previous studies, there have been two pieces of
evidence supporting that serum TgAbs actually affect the diagnositc performances of FNA-Tg
to detect LNMs in patients with thyroid cancer [21, 22]. Cappelli et al. reported two cases in
which the detection of FNA-Tg switched from undetectable to detectable levels in metastatic
LNs after recombinant human thyrotropin stimulation in the presence of high levels of serum
b, 38.3 [= exp (4.256)] ng/mL in c, respectively). The abscissa represents the logarithmically transformed
values of FNA-Tgs to adjust for skewed distributions. sTgAb-, undetectable serum TgAbs; sTgAb+,
detectable serum TgAbs; All groups, sTgAb- and sTgAb+ groups being included together; FNA-Tg,
thyroglobulin level in FNA washout fluid; LN, lymph node.
doi:10.1371/journal.pone.0131096.g001
Table 2. Diagnostic performances of FNA-Tg according to the presence of serum TgAbs.
sTgAb- a sTgAb+a sTgAb+b p valuec p valued
Sensitivity, % 91.1 (85.2–97.0) 75.0 (53.8–96.2) 75.0 (53.8–96.2) 0.057 0.057
Speciﬁcity, % 100 (100–100) 87.5 (71.3–100) 93.8 (81.9–100) <0.001 0.005
PPV, % 100 (100–100) 85.7 (67.4–100) 92.3 (77.8–100) <0.001 0.009
NPV, % 93.6 (89.3–97.9) 77.8 (58.6–97.0) 79.0 (60.6–97.3) 0.021 0.029
Accuracy, % 96.1 (93.5–98.8) 81.3 (67.7–94.8) 83.3 (70.0–96.7) 0.001 0.006
AUC 0.956 (0.924–0.983) 0.814 (0.670–0.941) 0.844 (0.682–0.962) 0.024 0.066
Data in parentheses are 95% conﬁdence intervals.
aCutoff value of FNA-Tg was 19.9 ng/mL.
bCutoff value of FNA-Tg was 38.3 ng/mL.
cp-value between the sTgAb- and sTgAb+ groups when applying the same FNA-Tg cutoff value of 19.9 ng/mL (sTgAb-a vs. sTgAb+ b).
dp-value between the sTgAb- group with a FNA-Tg cutoff value of 19.9 ng/mL and the sTgAb+ group with a FNA-Tg cutoff value of 38.3 ng/ mL (sTgAb-a
vs. sTgAb+ b).
FNA-Tg, thyroglobulin level in FNA washout ﬂuid; sTgAb-, undetectable serum TgAbs; sTgAb+, detectable serum TgAbs; PPV, positive predictive value;
NPV, negative predictive value; AUC, the area under the ROC curves.
doi:10.1371/journal.pone.0131096.t002
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TgAbs [21]. Because serum TgAbs could fully prevent the detection of FNA-Tg in LNMs by
saturating all the Tgs in the lymph nodes, they hypothesized that FNA-Tgs increased after thy-
rotropin stimulation, resulting in detectable levels in FNA washout fluid, even with the same
titer of serum TgAbs [21]. Recently, Jeon et al. demonstrated a significant negative correlation
between serum TgAbs and FNA-Tg levels, suggesting the possibility of interference by serum
TgAbs [22]. On Tg stains of 4 malignant LNs from patients with serum TgAbs, the tissues were
positive for Tg immunoreactivity although the FNA-Tg values were 10 ng/mL or less [22].
However, Jeon et al. still supported the clinical necessity of FNA-Tg tests in patients with
serum TgAbs although they did not analyze the additional values of FNA-Tg to FNA according
to the presence of serum TgAbs [22].
In this study, we investigated whether serum TgAbs might affect the detection of FNA-Tgs
in diagnosing LNMs in patients who had undergone thyroidectomy and radioactive iodine
ablation. Serum TgAbs significantly interacted with FNA-Tg measurements for LNM diagnosis
on logistic regression analyses. The serum TgAbs modified the association between FNA-Tgs
and LNMs, by decreasing ORs from 2.685–2.780 in the sTgAb- group to 1.707–1.779 in the
sTgAb+ group. We obtained different cutoff values of FNA-Tgs according to the presence of
serum TgAbs, such as 19.9 ng/mL in the sTgAb- group and 38.3 ng/mL in the sTgAb+ group.
This higher cutoff value of FNA-Tg (38.3 ng/mL) in the sTgAb+ group could be explained by
sTgAb interference, which would lead to an increased cutoff value of FNA-Tg for diagnosing
metastatic lymph nodes. It means that sTgAb would not completely interfere with higher
FNA-Tg levels. We also compared the diagnostic performances of FNA-Tg according to the
absence or presence of serum TgAbs using two different optimal cutoff values of FNA-. The
diagnostic performances of FNA-Tg were then compared according to the presence of serum
TgAbs (Table 2). In the sTgAb+ group using a cutoff value of 38.3 ng/mL, all of the diagnostic
values were decreased than those of the sTgAb- group with a cutoff value of 19.9 ng/mL. We
also compared diagnostic performances between FNA and the combination of FNA with
FNA-Tg in the sTgAb- and sTgAb+ groups, because of the interference of serum TgAbs in
Table 3. Diagnostic performance comparison between FNA alone and the combination of FNAwith FNA-Tg.
All (n = 239) sTgAb- (n = 207) sTgAb+ (n = 32)
FNA FNA with
FNA-Tga
p
value
FNA FNA with
FNA-Tga
p
value
FNA FNA with
FNA-Tgb
p
value
Sensitivity,
%
91.5 (86.2–
96.8)
97.2 (94.0–100) 0.012 91.1 (85.2–
97.0)
96.7 (93.0–100) 0.021 93.8 (81.9–
100)
100 (100–100) 0.302
Speciﬁcity,
%
100 (100–100) 98.5 (96.4–100) 0.154 100 (100–100) 100 (100–100) > 0.999 100 (100–100) 93.8 (81.9–100) 0.302
PPV, % 100 (100–100) 98.1 (95.5–100) 0.153 100 (100–100) 100 (100–100) > 0.999 100 (100–100) 94.1 (82.9–100) 0.303
NPV, % 93.7 (89.7–
97.7)
97.8 (95.3–100) 0.013 93.6 (89.3–
97.9)
97.5 (94.7–100) 0.023 94.1 (82.9–
100)
100 (100–100) 0.303
Accuracy, % 96.2 (93.8–
98.7)
97.9 (96.1–
99.7)
0.156 96.1 (93.5–
98.8)
98.6 (96.9–100) 0.024 96.9 (90.9–
100)
96.9 (90.9–100) > 0.999
AUC 0.958 (0.930–
0.981)
0.978 (0.958–
0.995)
0.072 0.955 (0.924–
0.983)
0.983 (0.961–
1.000)
<0.001 0.970 (0.893–
1.000)
0.967 (0.893–
1.000)
0.9
Data in parentheses are 95% conﬁdence intervals.
aCutoff value of FNA-Tg was 19.9 ng/mL.
bCutoff value of FNA-Tg was 38.3 ng/mL.
All, groups including sTgAb- and sTgAb+; sTgAb-, undetectable serum TgAbs; sTgAb+, detectable serum TgAbs; FNA, ﬁne needle aspiration; FNA-Tg,
thyroglobulin level in FNA washout ﬂuid; PPV, positive predictive value; NPV, negative predictive value; AUC, the area under the ROC curves.
doi:10.1371/journal.pone.0131096.t003
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FNA-Tg measurements and decreased diagnostic performances of FNA-Tg in the sTgAb+
group (Table 3) [7, 10, 13, 22]. In the sTgAb- group, sensitivity, NPV, accuracy and AUC were
all significantly increased in the combination of FNA with FNA-Tg group, compared to the
FNA only group. However, in the sTgAb+ group, the diagnostic performances of the combina-
tion of FNA-Tg to FNA showed decreased specificity and PPV than FNA alone, even though it
showed superior sensitivity and NPV without statistical significance. Therefore, serum TgAbs
likely interferes with FNA-Tg analysis and a negative result on FNA-Tg should be cautiously
evaluated especially when the serum levels of TbAbs rise. And also the evaluation of TgAbs lev-
els should be considered before performing FNA-Tg studies and further studies are needed to
define appropriate critical threshold levels of FNA-Tg according to the TgAbs levels.
There were a few limitations in this study. First, this study was a retrospective study, and we
included patients who underwent FNA, additional Tg measurements in FNA washouts, and
lymph node dissections or imaging follow-ups for more than 1 year. Therefore, a selection bias
could exist. Second, the small sample size of the sTgAb+ group (32 of 239 LNs) could reduce
the statistical power of this study. Further studies with more patients will be needed to validate
the diagnostic value of additional FNA-Tg measurements in the presence of serum TgAbs to
diagnose LNMs. Third, a large proportion of benign LNs (133 of 239 LNs) were considered
negative for LNMs based on imaging surveillance alone without surgical confirmation, which
leaves the possibility for malignant LNs in some cases. And we suggested LNs with atypical
cells on cytology, as a positive result even without final pathologic confirmation of malignancy
according to the clinical and radiological evidence. The last limitation to be discussed is the cut-
off value of 60 IU/L applied for serum TgAbs. There is debate that the cutoff value might be
too high to detect the interfering effect of serum TgAbs. A previous study which used the same
cutoff value also mentioned that any detectable level of serum TgAbs could influence the detec-
tion of Tg relevant to its level, and another study mentioned that the proof of interfering effect
of TgAbs might be depend on cutoff value and methods because the reference ranges were not
established yet [24, 29]. However, the value of 60 IU/L was the manufacturer-recommended
cutoff value, and we applied the same cutoff value as recommended and as applied in a previ-
ous study. Further studies are needed to validate the true impact of serum TgAbs on the detec-
tion of FNA-Tg according to its level and different cutoff values.
In conclusion, serum TgAbs may interfere with FNA-Tg studies and caution is advised, but
more work is needed to understand its true impact on management.
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